Personalis Share Holder Equity 2018-2024 | PSNL

Personalis share holder equity from 2018 to 2024. Share holder equity can be defined as the sum of preferred and common equity items
Personalis Annual Share Holder Equity
(Millions of US $)
2023 $129
2022 $218
2021 $310
2020 $195
2019 $107
2018 $-106
2017 $0
Personalis Quarterly Share Holder Equity
(Millions of US $)
2024-06-30 $112
2024-03-31 $121
2023-12-31 $129
2023-09-30 $151
2023-06-30 $176
2023-03-31 $194
2022-12-31 $218
2022-09-30 $242
2022-06-30 $265
2022-03-31 $287
2021-12-31 $310
2021-09-30 $325
2021-06-30 $339
2021-03-31 $348
2020-12-31 $195
2020-09-30 $204
2020-06-30 $93
2020-03-31 $99
2019-12-31 $107
2019-09-30 $111
2019-06-30 $117
2019-03-31 $0
2018-12-31
2018-09-30 $0
2018-06-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00